Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

DLDN-Bench: A Benchmark Framework for Deep Learning de Novo Peptide Sequencing in Proteomics

Created on 12 Jun 2026

Authors

Schneider, J., Hartwig, S., Chadt, A., Lehr, S., Al-Hasani, H., Turewicz, M.

Abstract

De novo peptide sequencing is an essential approach for analyzing mass spectrometry data because it enables the identification of novel peptides without relying on protein sequence databases. Recent advances in deep learning have substantially improved the performance of de novo sequencing methods, but the rapid emergence of new models has led to heterogeneous evaluation practices and limited comparability. To address this, we introduce DLDN-Bench, a benchmark framework including a set of benchmark datasets derived from human muscle biopsy mass spectrometry data retrieved from PRIDE and annotated through consensus across multiple widely used database search engines. Using these datasets, we systematically benchmark recent deep learning-based de novo sequencing tools alongside traditional approaches. Performance is assessed using established metrics, including precision and coverage relative to a pseudo-ground truth defined by cross-engine agreement. To demonstrate the utility of DLDN-Bench, we benchmark four recent deep learning models and make all results publicly available. This benchmark framework provides a standardized basis for comparing state-of-the-art methods and offers an extensible resource for evaluating future tools in de novo peptide sequencing.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 12 Jun 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 20
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement